Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

Published Date: 28 Jun 2024

Our panel of experts discusses mosunetuzumab/polatuzumab vedotin for relapsed/refractory patients

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A new therapeutic approach could help tackle radiation resistance in childhood brain tumors

2.

Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer

3.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

4.

After HSCT, a longer course of letermovir prophylaxis decreased the risk of cytomegalovirus infection.

5.

Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot